Found: 357
Select item for more details and to access through your institution.
Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 5, p. 701, doi. 10.1007/s41669-024-00497-4
- By:
- Publication type:
- Article
Tofacitinib in the treatment of ulcerative colitis: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (ÖGGH).
- Published in:
- Wiener Klinische Wochenschrift, 2023, v. 135, n. 1/2, p. 1, doi. 10.1007/s00508-022-02110-2
- By:
- Publication type:
- Article
Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach.
- Published in:
- Drug Development Research, 2024, v. 85, n. 4, p. 1, doi. 10.1002/ddr.22220
- By:
- Publication type:
- Article
Computational drug repositioning of atorvastatin for ulcerative colitis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Vedolizumab for acute gastrointestinal graft-versushost disease: A systematic review and meta-analysis.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1025350
- By:
- Publication type:
- Article
A broad cuproptosis landscape in inflammatory bowel disease.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1031539
- By:
- Publication type:
- Article
Editorial: monitoring vedolizumab trough serum concentration in inflammatory bowel disease—following the fate of anti‐TNF‐alpha agents?
- Published in:
- 2018
- By:
- Publication type:
- Editorial
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 8, p. 1117, doi. 10.1111/apt.14567
- By:
- Publication type:
- Article
Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab—Authors' reply.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 7, p. 896, doi. 10.1111/apt.14550
- By:
- Publication type:
- Article
Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 7, p. 906, doi. 10.1111/apt.14548
- By:
- Publication type:
- Article
Editorial: biologic therapy for chronic pouchitis – are we beginning to meet the unmet need?
- Published in:
- 2018
- By:
- Publication type:
- Editorial
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 6, p. 753, doi. 10.1111/apt.14525
- By:
- Publication type:
- Article
Predicting corticosteroid‐free endoscopic remission with vedolizumab in ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 6, p. 763, doi. 10.1111/apt.14510
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- 2018
- Publication type:
- Table of Contents
Vedolizumab in the treatment of chronic, antibiotic‐dependent or refractory pouchitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 5, p. 581, doi. 10.1111/apt.14479
- By:
- Publication type:
- Article
Editorial: tofacitinib and biologics for moderate‐to‐severe ulcerative colitis—what is best in class? Authors’ reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 4, p. 540, doi. 10.1111/apt.14486
- By:
- Publication type:
- Article
Postoperative outcomes in vedolizumab‐treated Crohn's disease patients undergoing major abdominal operations.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 5, p. 573, doi. 10.1111/apt.14459
- By:
- Publication type:
- Article
Editorial: vedolizumab as a treatment and cause of extra‐intestinal manifestations of inflammatory bowel disease.
- Published in:
- 2018
- By:
- Publication type:
- Editorial
Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 4, p. 485, doi. 10.1111/apt.14419
- By:
- Publication type:
- Article
Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 46, n. 10, p. 1019, doi. 10.1111/apt.14320
- By:
- Publication type:
- Article
Editorial: how effective is vedolizumab in the 'real world'?
- Published in:
- 2017
- By:
- Publication type:
- Editorial
Editorial: gut selective immunosuppression-is it a double edged sword?
- Published in:
- 2017
- By:
- Publication type:
- Editorial
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 46, n. 3, p. 310, doi. 10.1111/apt.14167
- By:
- Publication type:
- Article
Editorial: gut selective immunosuppression-is it a double edged sword? Authors' reply.
- Published in:
- 2017
- By:
- Publication type:
- Editorial
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 46, n. 1, p. 3, doi. 10.1111/apt.14075
- By:
- Publication type:
- Article
Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply.
- Published in:
- 2017
- By:
- Publication type:
- Editorial
Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum?
- Published in:
- 2017
- By:
- Publication type:
- Editorial
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 8, p. 1058, doi. 10.1111/apt.13995
- By:
- Publication type:
- Article
Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 7, p. 941, doi. 10.1111/apt.13960
- By:
- Publication type:
- Article
Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 2, p. 264, doi. 10.1111/apt.13852
- By:
- Publication type:
- Article
Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 2, p. 376, doi. 10.1111/apt.13861
- By:
- Publication type:
- Article
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2016, v. 44, n. 11/12, p. 1199, doi. 10.1111/apt.13813
- By:
- Publication type:
- Article
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2016, v. 43, n. 10, p. 1090, doi. 10.1111/apt.13594
- By:
- Publication type:
- Article
Corrigendum.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 9, p. 1135, doi. 10.1111/apt.13365
- Publication type:
- Article
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 2, p. 188, doi. 10.1111/apt.13243
- By:
- Publication type:
- Article
Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 41, n. 12, p. 1227, doi. 10.1111/apt.13215
- By:
- Publication type:
- Article
Vedolizumab‐induced acne in inflammatory bowel disease.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting.
- Published in:
- European Journal of Pediatrics, 2024, v. 183, n. 1, p. 313, doi. 10.1007/s00431-023-05255-y
- By:
- Publication type:
- Article
Correction to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
- Published in:
- European Journal of Pediatrics, 2021, v. 180, n. 9, p. 3029, doi. 10.1007/s00431-021-04063-6
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Curcumin chitosan microspheres regulate Th17/Treg balance via IGF2BP1- mediated m6A modification of LRP5 in ulcerative colitis.
- Published in:
- Iranian Journal of Basic Medical Sciences, 2024, v. 27, n. 10, p. 1276, doi. 10.22038/ijbms.2024.76332.16535
- By:
- Publication type:
- Article
Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease.
- Published in:
- Therapeutic Advances in Gastroenterology, 2020, v. 13, p. 1, doi. 10.1177/1756284820979765
- By:
- Publication type:
- Article
Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland.
- Published in:
- Therapeutic Advances in Gastroenterology, 2020, v. 13, p. 1, doi. 10.1177/1756284820941179
- By:
- Publication type:
- Article
Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario.
- Published in:
- Therapeutic Advances in Gastroenterology, 2020, v. 13, p. 1, doi. 10.1177/1756284820936536
- By:
- Publication type:
- Article